Radiofrequency-Guided Localization in Patients With Abnormal Breast Tissue Undergoing Lumpectomy
Primary Purpose
Breast Neoplasm
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Lumpectomy
Questionnaire Administration
Radiofrequency-Guided Localization
Sponsored by
About this trial
This is an interventional diagnostic trial for Breast Neoplasm
Eligibility Criteria
Inclusion Criteria:
- Have had stereotactic or ultrasound-guided biopsy with marker placement
- Have a lesion or biopsy marker that is visible under ultrasound
- Have a surgical target =< 6 cm from the skin when lying supine
- Have a discreet surgical target
- Have a lesion in which the center/focal area is defined
- Have the ability to understand and the willingness to sign a written informed consent document
- Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status will not be used as an inclusion criterion
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Require more than one localization needle for localization of the surgical target (bracket localization)
- Have undergone previous open surgical biopsy, lumpectomy, or mastectomy in the operative breast
- Have a prosthesis/implant in the operative breast
- Have a cardiac pacemaker or defibrillator device
- Be contraindicated for surgery
- Be pregnant
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Diagnostic (radiofrequency-guided localization)
Arm Description
Patients undergo radiofrequency-guided localization comprising RFID tag placement before lumpectomy and interactive detection of tag using RFID reader during lumpectomy.
Outcomes
Primary Outcome Measures
Localization success, defined as the surgical target visualized in the removed specimen AND the RFID tag removed from the patient's breast
Will be summarized using descriptive statistics, including total numbers, percentages, means, and proportions.
Secondary Outcome Measures
Feedback solicited from the radiologist and surgeon
Feedback solicited from the radiologist and surgeon will be summarized using qualitative methods. Each questionnaire will be reviewed for both positive and negative responses and summarized.
Full Information
NCT ID
NCT02432118
First Posted
April 28, 2015
Last Updated
January 31, 2017
Sponsor
Stanford University
Collaborators
National Cancer Institute (NCI)
1. Study Identification
Unique Protocol Identification Number
NCT02432118
Brief Title
Radiofrequency-Guided Localization in Patients With Abnormal Breast Tissue Undergoing Lumpectomy
Official Title
A Feasibility Study of Radiofrequency Identification (RFID) Localization of Breast Lesions
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Insufficient resources
Study Start Date
May 2015 (undefined)
Primary Completion Date
February 2016 (Anticipated)
Study Completion Date
May 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Stanford University
Collaborators
National Cancer Institute (NCI)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This pilot clinical trial studies the use of the radiofrequency-guided localization in patients with abnormal breast tissue undergoing lumpectomy (a type of breast-sparing surgery). The radiofrequency identification localization system consists of an implantable radiofrequency identification tag and a hand-held radiofrequency reader to mark abnormal breast tissue before surgery and later surgically retrieve them. Radiofrequency-guided localization may make it easier to find and remove abnormal breast tissue during lumpectomy.
Detailed Description
PRIMARY OBJECTIVES:
I. To obtain human clinical data in order to demonstrate that the Radiofrequency Identification (RFID) Localization System performs as intended as a localization device for marking and retrieving a surgical target in the breast.
SECONDARY OBJECTIVES:
I. To solicit feedback from the radiologists and surgeons regarding the process and use of the RFID system.
OUTLINE:
Patients undergo radiofrequency-guided localization comprising RFID tag placement before lumpectomy and interactive detection of tag using RFID reader during lumpectomy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasm
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diagnostic (radiofrequency-guided localization)
Arm Type
Experimental
Arm Description
Patients undergo radiofrequency-guided localization comprising RFID tag placement before lumpectomy and interactive detection of tag using RFID reader during lumpectomy.
Intervention Type
Procedure
Intervention Name(s)
Lumpectomy
Other Intervention Name(s)
Lumpectomy of Breast, partial mastectomy
Intervention Description
Undergo lumpectomy
Intervention Type
Other
Intervention Name(s)
Questionnaire Administration
Intervention Description
Ancillary studies
Intervention Type
Procedure
Intervention Name(s)
Radiofrequency-Guided Localization
Intervention Description
Undergo radiofrequency-guided localization
Primary Outcome Measure Information:
Title
Localization success, defined as the surgical target visualized in the removed specimen AND the RFID tag removed from the patient's breast
Description
Will be summarized using descriptive statistics, including total numbers, percentages, means, and proportions.
Time Frame
At time of surgery
Secondary Outcome Measure Information:
Title
Feedback solicited from the radiologist and surgeon
Description
Feedback solicited from the radiologist and surgeon will be summarized using qualitative methods. Each questionnaire will be reviewed for both positive and negative responses and summarized.
Time Frame
Up to 12 months after lumpectomy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Have had stereotactic or ultrasound-guided biopsy with marker placement
Have a lesion or biopsy marker that is visible under ultrasound
Have a surgical target =< 6 cm from the skin when lying supine
Have a discreet surgical target
Have a lesion in which the center/focal area is defined
Have the ability to understand and the willingness to sign a written informed consent document
Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status will not be used as an inclusion criterion
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
Require more than one localization needle for localization of the surgical target (bracket localization)
Have undergone previous open surgical biopsy, lumpectomy, or mastectomy in the operative breast
Have a prosthesis/implant in the operative breast
Have a cardiac pacemaker or defibrillator device
Be contraindicated for surgery
Be pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jafi Lipson
Organizational Affiliation
Stanford University Hospitals and Clinics
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Radiofrequency-Guided Localization in Patients With Abnormal Breast Tissue Undergoing Lumpectomy
We'll reach out to this number within 24 hrs